BIO Asia–Taiwan 2025 亞洲生技大會

BIO Asia–Taiwan 2025 亞洲生技大會

TEACHER

Hung-Kai Kevin Chen

​​


Session A-12 – Alzheimer’s Disease Forum

Date:25 July (Friday)
Time15:20 – 15:30(GMT+8)

Hung-Kai Kevin Chen

CEO
Elixiron Immunotherapeutics


​​​
Dr. Hung-Kai (Kevin) Chen, M.D., Ph.D., is the Founder, CEO, and Chairman of Elixiron Immunotherapeutics, a clinical-stage biopharmaceutical company advancing novel immunomodulatory therapies for neurodegenerative and autoimmune diseases. With over 25 years of cross-disciplinary experience in translational medicine, drug discovery, and clinical development, Dr. Chen has led multiple first-in-class therapeutic programs from concept to clinic.
Under his leadership, Elixiron has developed two proprietary antibody therapeutics that have entered clinical trials—one targeting microglial modulation in Alzheimer’s disease and another addressing autoimmune mechanisms in vitiligo. His work has been recognized internationally, including receiving the Alzheimer’s Association’s Part-the-Cloud Award and the 2020 National Innovation Award.
Prior to founding Elixiron, Dr. Chen held leadership roles at Eusol Biotech, the Development Center for Biotechnology (DCB), and GlaxoSmithKline (GSK), where he contributed to translational strategies and early-phase biologics development. His academic appointments include research positions at the Gladstone Institutes (UCSF) and National Yang-Ming University.
Dr. Chen received his M.D., M.Sc., and Ph.D. degrees from National Yang-Ming University and completed postdoctoral training in neuroscience and immunology at Baylor College of Medicine and the Howard Hughes Medical Institute in the United States. He has authored high-impact publications in Cell, Nature Medicine, and Cancer Discovery, with research contributions spanning neuroimmunology, antibody engineering, and translational neuroscience.

Suppression of Microglia-Mediated Neuroinflammation

.

​​​